NCT06488924View on ClinicalTrials.gov

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 5, 2024

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
Mucopolysaccharidosis III-B
Interventions
DRUG

JR-446

IV infusion

Trial Locations (3)

Unknown

RECRUITING

Hiroshima University Hospital, Hiroshima

RECRUITING

University of the Ryukyus Hospital, Okinawa

RECRUITING

National Center for Child Health and Development, Tokyo

Sponsors
All Listed Sponsors
lead

JCR Pharmaceuticals Co., Ltd.

INDUSTRY

NCT06488924 - An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB | Biotech Hunter | Biotech Hunter